Transcriptomics Identifies a Small Set of Circulating Biomarkers and Signaling Pathways Dysregulated in Hypertrophic Cardiomyopathy.
Abstract
Background
It is sometimes challenging to distinguish hypertrophic cardiomyopathy (HCM) from other cardiomyopathies with left ventricular hypertrophy (LVH). At present, no circulating biomarkers to distinguish HCM have been established.
Objectives
The authors aimed to identify plasma microRNA (miRNA) biomarkers unique to HCM.
Methods
In this multicenter case-control study, the authors performed comprehensive plasma transcriptomics profiling in cases with HCM and controls with hypertensive LVH, transthyretin amyloid cardiomyopathy (ATTR-CM), and aortic stenosis (AS). For each disease group, they chronologically split the patients into training and test sets. The authors identified miRNAs that were significantly (Benjamini-Hochberg-adjusted P < 0.05) upregulated or downregulated in HCM compared with hypertensive LVH. They made the same comparisons between HCM and ATTR-CM and between HCM and AS. They determined miRNAs that were consistently upregulated or downregulated in HCM throughout all 3 comparisons. Then, they selected miRNAs independently associated with HCM after adjusting for potential confounders. Using the selected miRNAs, the authors developed a logistic regression model to distinguish HCM in the training set. They calculated the area under the receiver-operating characteristic curve in the test set.
Results
The authors analyzed 2,656 miRNAs in patients with HCM (n = 294), hypertensive LVH (n = 321), ATTR-CM (n = 167), and AS (n = 38). They identified 3 miRNAs (miR-454-3p, miR-98-5p, and miR-5581-3p). The logistic regression model using the 3 miRNAs had an area under the receiver-operating characteristic curve of 0.95 (95% CI: 0.93-0.97) with a sensitivity of 0.95 and a specificity of 0.90 in the test set.
Conclusions
Comprehensive plasma transcriptomics profiling identified a small set of circulating miRNAs to distinguish HCM from other cardiomyopathies with LVH.